Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Girones Sarrio, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab + ipilimumab (N + I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Meeting Abstract

    Albiges, L.; Tannir, N.; Burotto, M.; McDermott, D. F.; Plimack, E. R.; Barthélémy, P.; Porta, C. G.; Powles, T. B.; Donskov, F.; George, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Lee, C. H.; Adachi, Y.; Ikezawa, H.; Li, S. D.; Funahashi, Y.; Minoshima, Y.; Kubiak, P.; Perini, R.; Ren, M.; Smith, A. D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
    Meeting Abstract

    Chowdhury, S.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A. H.; McDermott, R.; Sautois, B.; Vogelzang, N. J.; Bambury, R.; Voog, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
    Meeting Abstract

    Madan, R. A.; Slovin, S.; Harshman, L. C.; Wei, X. X.; Bilusic, M.; Karzai, F. H.; Donahue, R. N.; Toney, N. J.; Strauss, J.; Cordes, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naive, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Msaouel, P.; Siefker-Radtke, A. O.; Sweis, R.; Mao, S.; Rosenberg, J. E.; Vaishampayan, U. N.; Rezazadeh Kalebasty, A.; Pili, R.; Bupathi, M.; Nordquist, L. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours
    Meeting Abstract

    Powderly, J.; Shimizu, T.; Lorusso, P.; Razak, A.; Miller, K. D.; Balar, A. V.; Bruix, J.; Michel, L. S.; Blaney, M.; Guan, X.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
    Meeting Abstract

    Schuler, M.; Tabernero, J.; Massard, C.; Vasudeva Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
    Meeting Abstract

    Leyvraz, S.; Yang, J. C. H.; Casali, P. G.; Castro, G.; Kim, E. S.; Lassen, U. N.; Lopez-Rios, F.; Penault-Llorca, F.; Pappo, A.; Rudzinski, E. R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Horvath, L.; Dorff, T.; Rettig, M.; Lolkema, M. P.; Machiels, J. P.; Rottey, S.; Autio, K.; Greil, R.; Adra, N.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save